Vaxcyte/$PCVX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Vaxcyte
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
Ticker
$PCVX
Sector
Primary listing
Employees
414
Headquarters
Website
Vaxcyte Metrics
BasicAdvanced
$5.4B
-
-$4.13
1.21
-
Price and volume
Market cap
$5.4B
Beta
1.21
52-week high
$112.69
52-week low
$27.66
Average daily volume
2M
Financial strength
Current ratio
11.106
Quick ratio
10.755
Long term debt to equity
2.59
Total debt to equity
2.795
Profitability
EBITDA (TTM)
-698.618
Management effectiveness
Return on assets (TTM)
-16.44%
Return on equity (TTM)
-21.65%
Valuation
Price to book
1.76
Price to tangible book (TTM)
1.76
Price to free cash flow (TTM)
-9.784
Free cash flow yield (TTM)
-10.22%
Free cash flow per share (TTM)
-4.252
Growth
Earnings per share change (TTM)
-10.11%
3-year earnings per share growth (CAGR)
17.26%
What the Analysts think about Vaxcyte
Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.
Bulls say / Bears say
As of June 30, 2025, Vaxcyte held approximately $2.83 billion in cash, cash equivalents, and investments, extending its funding runway to mid-2028 due to disciplined capital allocation.
After an FDA End-of-Phase 2 meeting and under its Breakthrough Therapy designation, Vaxcyte has finalized the VAX-31 Phase 3 adult program, selecting a high-dose regimen for a pivotal non-inferiority study starting in Q4 2025. This positions it as a potential new standard of care.
The modified VAX-31 infant Phase 2 randomized, dose-finding study has progressed to the third and final stage, now enrolling with the optimized dose arm. The company aims to deliver topline immunogenicity and booster data by mid-2027, with the potential to cover about 92% of invasive pneumococcal disease in U.S. children under five.
Net loss for Q2 2025 widened to $166.6 million from $128.7 million a year earlier, with R&D expenses rising to $194.2 million and G&A to $32.0 million, highlighting increased cash burn and execution risk ahead of pivotal Phase 3 data.
Vaxcyte halted development beyond preclinical stages for VAX-A1 (Group A Strep) and VAX-GI (Shigella), and discontinued VAX-PG (periodontal disease), narrowing its pipeline and making it increasingly reliant on the success of its PCV franchise.
Capital and facility buildout costs for the Lonza manufacturing suite reached $290.6 million as of June 30, 2025, with total completion projected at $300–350 million by early 2026. This poses potential pressure on liquidity and may divert resources from R&D.
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
Vaxcyte Financial Performance
Revenues and expenses
Vaxcyte Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vaxcyte stock?
Vaxcyte (PCVX) has a market cap of $5.4B as of October 25, 2025.
What is the P/E ratio for Vaxcyte stock?
The price to earnings (P/E) ratio for Vaxcyte (PCVX) stock is 0 as of October 25, 2025.
Does Vaxcyte stock pay dividends?
No, Vaxcyte (PCVX) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Vaxcyte dividend payment date?
Vaxcyte (PCVX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vaxcyte?
Vaxcyte (PCVX) has a beta rating of 1.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.